ChatGPT

Perplexity

Gemini

Claude

Grok

The Accredo® mobile app offers Accredo patients the convenience of managing specialty medications how you want, when you want. With the Accredo mobile app, you can:
 
•	Order specialty medication refi

Improve you and your family’s health, reduce your healthcare costs and increase your medication compliance.

The MediVera Compounding Rx app by PCCA transforms how we help you to improve your health o

Introducing HalfLife for IOS: a precision tracking tool designed to help users understand compound half-lives and pharmacokinetics through a simple, structured interface.
Whether you're managing compl

Why Recursion Pharmaceuticals abandoned cell painting for brightfield imaging

Recursion Pharmaceuticals releases 450GB of Covid-19 microscopy images

Case Study on Recursion Pharmaceuticals

Recursion Pharmaceuticals files for $100M IPO

Recursion Pharmaceuticals Price Target Update Feb 26 2026

Recursion Pharmaceuticals

Recursion Pharmaceuticals will be around $50 in 2 years! Look what happened to a no name biotech stock called “MINK THERAPEUTICS “ today!

Do we now have the right people at Recursion Pharmaceuticals ! Former CEO stepped down! CMO is stepping down as well! They are being replaced with very qualified people! Najat Khan an amazing and talented CEO and Vicki Goodman M.D. who’s a very certified and respected professional in her field?

Vanguard, blackrock, state street all increase shares in RECURSION PHARMACEUTICALS!

IS RECURSION PHARMACEUTICALS THE MOST UNDERRATED STOCK EVER?

Recursion pharmaceuticals

rxrx

RecursionPharma

RECURSION PHARMACEUTICALS, INC.

Biological Products, (No Diagnostic Substances)

Welcome to Ro. Healthcare designed to help you feel your best and achieve your goals. 

On Ro, you can connect with Ro-affiliated, US-licensed healthcare professionals, 100% online. Get world-class tr

Teladoc Health connects you with complete care, at your convenience and an affordable cost. You’ll find what you need to get well—like 24/7 care—alongside primary care, therapy and programs proven to 

With the Farmacias del Ahorro App, you will have well-being, health, prevention and beauty  at your fingertips. Browse through the different product categories and find what you are looking for. Scan 

insilico Pathway Activation Network Decomposition Analysis (iPANDA) package. Owned by Insilico Medicine Inc. iPANDA is a pathway analysis method that aids interpretation of large-scale gene expression data. The method introduced here includes coexpression analysis and gene importance estimation to robustly identify relevant pathways and biomarkers for patient stratification.

ipanda

In silico model from Trujillo CA, Adams JW, Negraes PD, Carromeu C, Tejwani L, Acab A, Tsuda B, Thomas CA, Sodhi N, Fichter KM, Romero S, Zanella F, Sejnowski TJ, Ulrich H, Muotri AR. Pharmacological reversal of synaptic and network pathology in human MECP2-KO neurons and cortical organoids. EMBO Molecular Medicine, e12523, 2020.

in_silico_bioANN

Тестовое задание в "Insilico Medicine"

ml-dfs-research

Test task to Insilico Medicine (Deep feature selection methods experiments)

deep-feature-selection

AI-driven toolset for IPF and aging research (inspired by Insilico Medicine research)

ai-ipf-aging-toolset

Insilico Medicine on Hugging Face

Insilico Medicine Uses Generative AI to Accelerate Drug Discovery

Insilico Medicine Announces an AI-Driven Protac R&D Collaboration with Arvinas

Insilico Medicine is a biotechnology company headquartered in Boston, Massachusetts, with additional facilities in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of Hong Kong, and in New York, at The Cure by Deerfield. The company combines genomics, big data analysis, and deep learning for in silico drug discovery.

https://en.wikipedia.org/wiki/Insilico_Medicine

Generative-AI drug developer Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly

Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly

Eli Lilly invests in AI-designed drugs in new deal with Insilico Medicine worth up to €2.39bn

Eli Lilly and Insilico Medicine ink $2.75 Billion pact: AI is officially taking over drug discovery

Eli Lilly sichert sich Rechte an KI-entwickelten Medikamenten Eli Lilly baut die Kooperation mit Insilico Medicine aus und sichert sich exklusive weltweite Rechte an KI-entwickelten Medikamenten. Das Volumen des Deals kann auf bis zu 2,75 Mrd. Dollar steigen.

Recursion Pharmaceuticals vs Insilico Medicine

Recursion Pharmaceuticals

About

Insilico Medicine

About

AI Visibility Head-to-Head

Also Compare

Track AI Visibility in Real Time